Form 8-K Elanco Animal Health For: May 21

May 27, 2026 5:01 PM EDT
false 0001739104 Elanco Animal Health Incorporated 0001739104 2026-05-21 2026-05-21 0001739104 us-gaap:CommonStockMember 2026-05-21 2026-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 21, 2026

 

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

 

Indiana  001-38661  82-5497352

(State or other jurisdiction
of incorporation)

  (Commission
File Number)
 

(I.R.S. Employer

Identification No.)

 

450 Elanco Circle

Indianapolis, Indiana

(Address of principal executive offices)

 

46221

(Zip Code)

 

Registrant’s telephone number, including area code: (877) 352-6261

 

Not Applicable

(Former Name or Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which
registered

Common stock, no par value   ELAN   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

Elanco Animal Health Incorporated (the “Company”) held its annual meeting of shareholders on May 21, 2026. Voting results for each matter submitted to a vote at the 2026 annual meeting are provided below.

 

Proposal 1. Election of Directors. All of the nominees nominated by the Board for director were elected to serve for a one-year term ending at the 2027 annual meeting of shareholders and until their respective successors are elected and qualified, by the votes set forth in the table below.

 

Class I Nominees  For   Against   Abstain   Broker Non-Votes 
Kapila K. Anand   375,459,071    91,840,502    655,918    15,365,167 
Paul Herendeen   441,252,058    26,575,629    127,804    15,365,167 

 

Class II Nominees  For   Against   Abstain   Broker Non-Votes 
Michael Harrington   373,406,333    94,421,261    127,897    15,365,167 
Lawrence Kurzius    442,964,897    24,863,542    127,052    15,365,167 
Kirk McDonald   440,842,458    26,978,663    134,370    15,365,167 

 

Proposal 2. The shareholders ratified the appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2026, by the votes set forth in the table below.

 

For   Against   Abstain 
480,470,647    2,611,450    238,561 

 

Proposal 3. The shareholders approved, by non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below.

 

For   Against   Abstain   Broker Non-Votes 
383,528,222    84,173,798    253,471    15,365,167 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Elanco Animal Health Incorporated
   
Date: May 27, 2026 By: /s/ Shiv O’Neill
    Name:  Shiv O’Neill
    Title:  Executive Vice President, General Counsel and Corporate Secretary

 

 

 

ATTACHMENTS / EXHIBITS

XBRL TAXONOMY EXTENSION SCHEMA

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION LABEL LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: tm2615566d1_8k_htm.xml



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings